ActiveGRANT

DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award

Department of DefenseDept. of the Army -- USAMRAA

AI Overview

Develop and validate clinical biomarkers and outcome measures to improve ALS clinical trials, including digital health tools like wearables and AI-enabled monitoring. Projects should incorporate patient community input and may target specific ALS subtypes or therapeutic classes.

This summary is AI-generated from the official solicitation.

Key Details

Agency
Department of Defense
Funding Amount
—
Release Date
May 4, 2026
Due Date
September 30, 2026

Official Description

<p><strong>Summary: </strong>The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients.</p><p...
View on official source

Change History

Opportunity AddedMay 4, 2026 at 1:45 PM

DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award

New Grants.gov opportunity: DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award

Get Alerts for Opportunities Like This

RallyProp monitors thousands of funding sources and sends instant alerts when opportunities match your technology and capabilities.

Start Free Trial